Bayer will present Phase III clinical trial data for cardiovascular, kidney, and stroke treatments at the ESC Congress 2026.
The presentations highlight late-breaking results for Kerendia in chronic kidney disease.
Bayer will release a pooled analysis of patients both with and without diabetes.
The company will also share a subanalysis of a specific patient subgroup.
These late-stage results act as primary catalysts for regulatory approvals and commercial drug potential.
Successful outcomes often bolster investor confidence in the company’s long-term growth prospects.